ABT Stock Falls -13% With A 5-day Losing Spree On Revenue Miss & Soft Guidance
Abbott Laboratories (ABT) – a developer and seller of diagnostic, pharmaceutical, and medical devices. – hit 5-day losing streak, with cumulative losses over this period amounting to a -13%. The company market cap has crashed by about $29 Bil over the last 5 days, and currently stands at $189 Bil.
The stock has YTD (year-to-date) return of 12.9% compared to 1% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Slide?
[1] Q4 2025 Earnings Report: Revenue Miss and Weaker Guidance
- Abbott Laboratories Stock: Join the Rally at a 19% Discount
- Pay Less, Gain More: RMD Tops Abbott Laboratories Stock
- Buy or Sell Abbott Laboratories Stock?
- Is Abbott Laboratories Stock Built to Withstand More Downside?
- How Did Abbott Fare In Q4 And What Lies Ahead?
- Pay Less, Gain More: RMD Tops Abbott Laboratories Stock
- Q4 revenue of $11.5B missed analyst consensus of $11.8B, driven by a 9% decline in the Nutrition segment.
- Q1 2026 adjusted EPS guidance of $1.12-$1.18 was below the consensus forecast of $1.20.
- Impact: Sharp stock price decline of over 6% on the day of the announcement, Significantly higher than average trading volume
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in ABT stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell ABT).
But here is the real interesting point.
You are reading about this -13% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for ABT stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ABT | S&P 500 |
|---|---|---|
| 1D | -10.0% | 0.5% |
| 5D (Current Streak) | -13.1% | -0.2% |
| 1M (21D) | -13.0% | 1.2% |
| 3M (63D) | -14.4% | 2.6% |
| YTD 2026 | -12.9% | 1.0% |
| 2025 | 12.9% | 16.4% |
| 2024 | 4.8% | 23.3% |
| 2023 | 2.3% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 43 S&P constituents with 3 days or more of consecutive gains and 29 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 29 | 16 |
| 4D | 7 | 5 |
| 5D | 2 | 6 |
| 6D | 2 | 2 |
| 7D or more | 3 | 0 |
| Total >=3 D | 43 | 29 |
Key Financials for Abbott Laboratories (ABT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $40.1 Bil | $42.0 Bil |
| Operating Income | $6.5 Bil | $6.8 Bil |
| Net Income | $5.7 Bil | $13.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $11.1 Bil | $11.4 Bil |
| Operating Income | $2.1 Bil | $2.1 Bil |
| Net Income | $1.8 Bil | $1.6 Bil |
The losing streak ABT stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.